VR Logo

Gain Therapeutics Inc. (GANX) download report


Healthcare | Biotechnology & Pharma Research

Gain Therapeutics Inc. (GANX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding.

IPO Date: 18-Mar-2021

Founder & Chairman: Dr. Khalid Islam Ph.D.

CEO, Pres & Director: Mr. Eric I. Richman M.B.A.

Listing: NASDAQ: GANX

Country: United States

Headquarters: Bethesda, MD

Website: https://www.gaintherapeutics.com

Key Facts

Market cap: $49.91 Mln

Revenue (TTM): $0.18 Mln

Earnings (TTM): $-14.71 Mln

Cash: $34.34 Mln

Total Debt: $1.50 Mln

Insider's Holding: 24.34%

Liquidity: Low

52 Week range: $2.33 - 10.48

Shares outstanding: 11,883,400

Stock Performance

Time Period Gain Therapeutics (GANX) S&P BSE Sensex S&P Small-Cap 600
YTD-34.07-8.99-19.23
1 month23.88-3.40-9.35
3 months-12.90-8.50-16.59
1 Year-64.900.89-17.36
3 Years--10.415.90
5 Years--11.435.77
10 Years--11.779.78
As on 30-Jun-2022